Immurin (Cyclosporine A), as an immuno-suppresant with a low aqueous solubility, has been widely used for the inhibition of graft rejection in organ transplant recipients. INNOPHARMAX OralPAS Cyclosporine A Softgel Capsules are designed to improve the bioavailability of Cyclosporine A by 10 fold via oral administration. In June 2009, INNOPHARMAX had been granted the product license from DOH to market IMMURINŽ in Taiwan
This cyclic polypeptide derived from a fungus is used as an immunosuppressive drug in organ transplant recipients. Cyclosporine binds to cyclophilin, a cytoplasmic protein, thereby interfering with calcium-dependent events including secretion of interleukin-2 (IL-2) by T lymphocytes. Since IL-2 is necessary for T cell replication, this drug is a potent inhibitor of T cell proliferation and thereby inhibits T cell-mediated immune responses. Little effect has been shown on direct B cell immune responses or on inflammation. Its toxic effects are primarily on renal and, to a lesser extent, hepatic function. In addition to methotrexate, methylprednisolone has also been utilized with cyclosporine to treat graft-versus-host disease, though T cell-directed immunotoxins have not proved to be of any benefit. A recently developed microemulsion formulation offers improved oral bioavailability, safety, and efficacy.